Zealand Pharma’s DKK 749 Million Shares Private Placement

Kromann Reumert has assisted the Joint Global Coordinators and Joint Bookrunners and the Co-Managers on the deal. Plesner has assisted Zealand Pharma A/S.

Zealand Pharma A/S announced the launch of a private placement of new ordinary shares, at a price to be determined through an accelerated book-building process. The private placement was completed on the same date and was priced at DKK 208 per share, a private placement of approximately 3.6 million new ordinary shares in Zealand Pharma A/S, yielding gross proceeds to the company of approximately DKK 749 million.

Zealand intends to use the net proceeds to help fund commercialization and pre-launch activities for Zealand’s late stage programs, accelerate development of the clinical pipeline, continued support for Zealand’s peptide platform, and for gen-eral corporate purposes.

Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company’s head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018 they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.

The Kromann Reumert’s core team included Marianne Philip (Picture), Christina Bruun Geertsen and Rune Morthorst.

The Plesner team included Thomas Holst Laursen, Micha Fritzen, Mikkel Rostock-Jensen and Hans Glent Abildgaard.

Involved fees earner: Christina Bruun Geertsen – Kromann Reumert; Rune Morthorst – Kromann Reumert; Marianne Philip – Kromann Reumert; Hans Glent Abildgaard – Plesner; Micha Fritzen – Plesner; Thomas Holst Laursen – Plesner; Mikkel Rostock-Jensen – Plesner;

Law Firms: Kromann Reumert; Plesner;

Clients: Bryan Garnier & Co Ltd ; Danske Bank; Goldman Sachs International; Jefferies; Nordea Bank Finland Plc; Nordea Danmark; Zealand Pharma A/S;